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Background
Atypical antipsychotics have been reported to induce
neuroleptic malignant syndrome (NMS). The precise
pathophysiologic mechanism is unknown but dopamine
blockage is pivotal. The serotoninergic action of atypical
antipsychotics may also been implicated because sero-
tonin may inhibit dopamine release and worsen hypo-
dopaminergic states. Amisulpride, which is a selective
D2/D3 receptor antagonist and has no affinity for sero-
tonin receptors may be less associated with the develop-
ment of NMS.
Materials and methods
A Medline search was conducted for articles published
till July 2009 relative to the induction of NMS by atypi-
cal antipsychotics in non-geriatric patients with schizo-
phrenia or schizoaffective disorder. We used the key-
words neuroleptic malignant syndrome and the names
of all first-line atypical antipsychotics, with the excep-
tion of paliperidone, which has been recently marketed.
Results
The number of the reported cases of atypical antipsy-
chotic-induced NMS in the defined population was
24 for risperidone, 18 for olanzapine, 7 for quetiapine, 9
for aripiprazole, and 5 for ziprasidone. Only two cases
of amisulpride-induced NMS were revealed. In one case
the patient was vulnerable to the induction of NMS
which had been caused by three different atypical
antipsychotics.
Conclusions
In the absence of large prospective studies regarding the
induction of NMS by atypical antipsychotics, which are
difficult to perform due to the rarity of the syndrome,
definite conclusions cannot be reached. Amisulpride
may be less than the other atypical antipsychotics asso-
ciated with NMS, and this may be accounted for by its
lack of serotoninergic action. Amisulpride may be a use-
ful option for re-started antipsychotic medication in
patients recovering from NMS.
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